David H. Johnson
Impact in
- Oncology top 0.05%
- Lung Cancer Research Studies
- Colorectal Cancer Screening and Detection
- Neutropenia and Cancer Infections
- Pulmonary and Respiratory Medicine top 0.1%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
- Oncology 120
- Lung Cancer Research Studies 73
- Cancer Treatment and Pharmacology 22
- Peptidase Inhibition and Analysis 15
- Cancer Diagnosis and Treatment 8
-
- Lung Cancer Treatments and Mutations 40
- Lung Cancer Diagnosis and Treatment 14
- Co-authors
- Joan H. Schiller (25 shared papers)Julie R. Brahmer (13 shared papers)Michael C. Perry (4 shared papers)Alan Sandler (16 shared papers)Robert J. Gray (4 shared papers)Afshin Dowlati (4 shared papers)Rogério Lilenbaum (1 shared paper)F. Anthony Greco (29 shared papers)
- Journals
- Journal of Clinical Oncology (37 papers)Lung Cancer (15 papers)Journal of Thoracic Oncology (14 papers)Cancer (10 papers)CHEST Journal (6 papers)
- Partner nations
- United StatesCanadaUnited Kingdom
In The Last Decade
David H. Johnson
236 papers receiving 20.4k citations
David H. Johnson's Hit Papers
Peers
Comparison fields: 5 of 190
- Oncology 12.2k
- Pulmonary and Respiratory Medicine 6.8k
- Cancer Research 1.4k
- Epidemiology 2.9k
- Pathology and Forensic Medicine 1.1k
Countries citing papers authored by David H. Johnson
This map shows the geographic impact of David H. Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David H. Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David H. Johnson more than expected).
Fields of papers citing papers by David H. Johnson
This network shows the impact of papers produced by David H. Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David H. Johnson. The network helps show where David H. Johnson may publish in the future.
Co-authors
The 25 scholars most cited alongside David H. Johnson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 249 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer Hit paper breakdown → | 2006 | 4683 |
| 2 | Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline From the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology Hit paper breakdown → | 2008 | 2429 |
| 3 | Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer Hit paper breakdown → | 1991 | 1171 |
| 4 | Twice-Daily Compared with Once-Daily Thoracic Radiotherapy in Limited Small-Cell Lung Cancer Treated Concurrently with Cisplatin and Etoposide Hit paper breakdown → | 1999 | 1091 |
| 5 | Impact of Cancer-Related Fatigue on the Lives of Patients: New Findings From the Fatigue Coalition Hit paper breakdown → | 2000 | 1030 |
| 6 | A Meta-Analysis of Thoracic Radiotherapy for Small-Cell Lung Cancer Hit paper breakdown → | 1992 | 991 |
| 7 | Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Hit paper breakdown → | 2015 | 708 |
| 8 | Final Results of Phase III Trial in Regionally Advanced Unresectable Non-Small Cell Lung Cancer Hit paper breakdown → | 2000 | 510 |
| 9 | Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Hit paper breakdown → | 2017 | 475 |
| 10 | 1992 | 435 | |
| 11 | 2007 | 262 | |
| 12 | 2011 | 236 | |
| 13 | 2012 | 235 | |
| 14 | 2001 | 231 | |
| 15 | 2007 | 226 | |
| 16 | 1990 | 195 | |
| 17 | 1996 | 182 | |
| 18 | 2004 | 182 | |
| 19 | 2002 | 176 | |
| 20 | 2014 | 174 |
About David H. Johnson
David H. Johnson is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Epidemiology, Molecular Biology and Surgery, having authored 249 papers that have together received 21.3k indexed citations. Recurring topics across this work include Lung Cancer Research Studies (73 papers), Lung Cancer Treatments and Mutations (40 papers), Neuroendocrine Tumor Research Advances (36 papers), Cancer Treatment and Pharmacology (22 papers), Cancer therapeutics and mechanisms (17 papers), Peptidase Inhibition and Analysis (15 papers), Lung Cancer Diagnosis and Treatment (14 papers) and Cancer Diagnosis and Treatment (8 papers). The work is most often cited by research in Oncology (12.2k citations), Pulmonary and Respiratory Medicine (6.8k citations), Cancer Research (1.4k citations), Epidemiology (2.9k citations) and Pathology and Forensic Medicine (1.1k citations). David H. Johnson has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Joan H. Schiller, Julie R. Brahmer, Michael C. Perry, Alan Sandler, Robert J. Gray, Afshin Dowlati, Rogério Lilenbaum, F. Anthony Greco, John D. Hainsworth and Henry Wagner. Their work appears in journals such as Journal of Clinical Oncology, Lung Cancer, Journal of Thoracic Oncology, Cancer and CHEST Journal.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.